BioTuesdays

Cardiff receives FDA Fast Track designation for onvansertib in mCRC

Cardiff Oncology

Cardiff Oncology (NASDAQ: CRDF) has announced that the FDA has granted Fast Track designation to onvansertib in combination with FOLFIRI/bevacizumab for the first-line treatment of adult patients with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC).

According to Cardiff, the designation is supported by clinical data from the ongoing randomized, controlled CRDF-004 clinical trial. The designation follows the FDA’s recent grant of Orphan Drug Designation to onvansertib for the treatment of chronic myelomonocytic leukemia and small cell lung cancer in October and November 2026, respectively.

In a statement, Mani Mohindru, PhD, president and CEO of Cardiff, commented, “Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need. Our randomized Phase 2 data give us confidence that onvansertib may provide an additive benefit to the current standard-of-care, as reflected in the maturing data from the ongoing trial. We look forward to working closely with the FDA as we advance onvansertib into our planned registrational trial and bringing this potential new treatment option to patients as quickly as possible.”

POWERED BY

Stay Ahead in Healthcare & Life Sciences